Pharma News

Keep updating your pharma knowledge
15 May 2017

DRL launches generic sofosbuvir & velpatasvir tablets for HCV in India

Dr Reddy’s Laboratories has launched the generic version of sofosbuvir 400mg and velpatasvir 100mg fixed-dose combination, indicated for the treatment of chronic hepatitis C, under a brand name Resof Total, in India.

Dr Reddy’s Resof Total tablets are available in bottle count size of 28.

Resof Total is used for the treatment of adult patients with chronic hepatitis C virus, genotype 1,2,3,4,5 or 6 infection  – without Cirrhosis or with compensated cirrhosis;  – with decompensated cirrhosis for use in combination with Ribavirin.

The sofosbuvir 400mg and velpatasvir 100mg fixed-dose combination is a generic version of Gilead’s brand Epclusa. treatment with this combination achieves a cure rate of more than 90% in all genotypes of hepatitis C virus (1,23,4, or 6). Achievement of higher cure rate with this combination in hepatitis C genotype 3 addresses a significant unmet need, since infection with genotype 3 of hepatitis C is upto 70% in Indian patients infected with hepatitis C.

Leave a Reply

The reCAPTCHA verification period has expired. Please reload the page.

Upskill Your Pharma Knowledge

Explore Next Gen Learning

Case Studies & Caselets | Simulation Based Learning | E-Lectures | Online Self Competency Assessments

Thank You for Subscription!